Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis

19 Aug 2025

Abstract excerpt

Identifying a reliable biomarker for amyotrophic lateral sclerosis (ALS) is crucial for clinical practice. Here, in this cross-sectional study, we used the Olink Explore 3072 platform to investigate plasma proteomics as a biomarker tool for this neurodegenerative condition. Thirty-three proteins were differentially abundant in the plasma of patients with ALS (n = 183) versus controls (n = 309). We replicated our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40830661
DOI: 10.1038/s41591-025-03890-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosisPMID 40830661Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosisSemantic proximity Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

Biomarkers for amyotrophic lateral sclerosis.Semantic proximity Read ↗

Muscle proteins in plasma associate to distinguished phenotypes in amyotrophic lateral sclerosisSemantic proximity Read ↗

Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic StudySemantic proximity Read ↗

Identification of a presymptomatic and early disease signature for Amyotrophic Lateral Sclerosis (ALS): protocol of the premodiALS studySemantic proximity Read ↗

Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisSemantic proximity Read ↗

Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic studySemantic proximity Read ↗

Proteomic profiling of CSF reveals stage-specific changes in Amyotrophic lateral sclerosis patientsSemantic proximity Read ↗

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.